Table 5.

Other sensitivity analyses (€/QALY)

Scenario	Denosumab vs. no treatment	Denosumab vs. generic alendronate	Denosumab vs. risedronate	Denosumab vs. strontium ranelate
Base casea	14,458	27,090	11,545	5,015
Discount rates (5%)	15,453	29,617	11,979	4,923
Discount rates (0%)	13,638	24,135	11,501	5,707
1 year DAPS persistence	15,937	35,114	12,983	4,313
Perfect persistence for all treatments	11,936	66,604	10,750	Cost saving
Denosumab maximum offset time 2 years	19,937	40,531	19,547	11,237
All treatments maximum offset time 2 years	19,937	34,920	16,953	9,896
10-year modeling horizon	13,833	32,993	8,752	10
GIAEsb for alendronate/risedronate	–	26,595	11236	–
Disutility from fractures decreased by 10%	16,362	30,633	13,057	5,685
20% of excess mortality attributable to fractures	10,951	25,340	7,587	228
10 year treatment duration	14,375	28,145	11,532	4,569
Mortality after hip and vertebral fractures 3 years	11,675	25,504	8,347	1,276
Mortality after hip and vertebral fractures 5 years	13,459	26,485	10,387	3,675

^aThe base case assumed discount rates of 3%, improved persistence for 3-years, maximum offset time of 5 years for all treatments, life-time horizon, no adverse events for any treatment, 5-year maximum treatment duration, 8 years of increased post-fracture mortality after hip and vertebral fractures

^bGastrointestinal adverse events